newsroom /

Milan, Italy May. 09, 2023

KLISBio to participate at 2023 FESSH-EFSHT Combined Congress With an e-poster presentation on SILKBridge

Milan, Italy (May 9th, 2023) – Today, KLISBio, a MedTech company challenging the status quo in regenerative medicine by leveraging a silk-based multidisciplinary technology platform, announced its attendance to 2023 FESSH-EFSHT Combined Congress organized by the Federation of European Societies for Surgery of the Hand and European Federation of Societies for Hand Therapy. The event will be held May 10 - 13, 2023 in Rimini – Italy. Antonio Alessandrino, CTO and Founder of KLISBio, and Gabriella Francavilla, Global Marketing Manager, will be attending the congress with the aim to cement current relationships and establish new ones with physicians and strategic partners.

KLISBio’s first product in pipeline is SILKBridge, a silk fibroin absorbable medical device for peripheral nerve repair. The Long-term follow-up study after digital nerve reconstruction with hybrid micro- and nanostructured silk fibroin nerve conduit on SILKBridge, conducted by Prof. Maurizio Calcagni, Deputy Clinic Director at Department of Plastic Surgery and Hand Surgery at University Hospital Zurich, will be presented as E-poster (Session SS81 Poster Session – Surgeons) during the congress.

The multilayered silk-based structure of SILKBridge is developed to confer ideal porosity and compression resistance to the device to promote safe nerve regeneration and functional recovery, while showing an optimized degradation profile that allows the conduit to support the nerve throughout its healing process. The inner and outer electrospun layers of SILKBridge are specifically designed to resorb faster and to promote cells adhesion. They mimic the nanoscale properties of fibrous components of the extracellular matrix that are ideal to enhance cellular interactions. The intermediate textile layer is modelled in open-mesh braided structures, and is designed to confer high mechanical performance and resistance to the device.

“The long-term follow-up of the premarket, monocentre first-in-human pilot study on SILKBridge has showed promising functional and patient satisfaction results. This represents an important starting point for KLISBio and paves the way to the development of SILKBridge future clinical strategy,” said Antonio Alessandrino, CTO and Founder of KLISBio. “I’d like to thank all of the participating subjects, Prof. Maurizio Calcagni, Principal Investigator, and KLISBio’s team members who have contributed to this study.”

KLISBio holds patents in Silk regenerated Fibroin + Native Silk Fibroin Pairing, Silk-based Composites and Core-Shell Silk Nanofibers. The Company is powered by a group of world leaders in MedTech including Grecchi, CEO; Antonio Alessandrino, President & Chief Technology Officer, Giuliano Freddi, Chief Scientific Officer e Lorenzo Sala, Co-founder and Facility & Procurement Manager. Since January 2022, Rodrigo Bianchi has been serving as Chairman of the Board, joining the company with more than three decades’ experience in global healthcare. In addition to its strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space.

About KLISBio:

KLISBio is a clinical-stage regenerative medicine company focused on developing innovative technology platforms entirely based on natural silk fibroin. The company, headquatered in Milan, Italy, currently has several assets under development, such as vascular graft, bone graft substitutes and rotator cuff repair.